208 related articles for article (PubMed ID: 18294113)
1. Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.
Bring P; Partovi N; Ford JA; Yoshida EM
Pharmacotherapy; 2008 Mar; 28(3):331-42. PubMed ID: 18294113
[TBL] [Abstract][Full Text] [Related]
2. Iron mobilization using chelation and phlebotomy.
Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ
J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
[TBL] [Abstract][Full Text] [Related]
3. Iron chelation therapy for patients with sickle cell disease and iron overload.
Inati A; Khoriaty E; Musallam KM; Taher AT
Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
[No Abstract] [Full Text] [Related]
4. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
[TBL] [Abstract][Full Text] [Related]
5. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Goldberg SL
Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
[TBL] [Abstract][Full Text] [Related]
6. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
7. Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation.
Meo A; Ruggeri A; La Rosa MA; Zanghì L; Morabito N; Duca L
Hemoglobin; 2006; 30(1):131-7. PubMed ID: 16540426
[TBL] [Abstract][Full Text] [Related]
8. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.
Cançado R; Melo MR; de Moraes Bastos R; Santos PC; Guerra-Shinohara EM; Chiattone C; Ballas SK
Eur J Haematol; 2015 Dec; 95(6):545-50. PubMed ID: 25684349
[TBL] [Abstract][Full Text] [Related]
9. Iron chelation therapy in the management of transfusion-related cardiac iron overload.
Fernandes JL
Transfusion; 2012 Oct; 52(10):2256-68. PubMed ID: 22404719
[TBL] [Abstract][Full Text] [Related]
10. Chelation therapy for iron overload.
Barton JC
Curr Gastroenterol Rep; 2007 Mar; 9(1):74-82. PubMed ID: 17335681
[TBL] [Abstract][Full Text] [Related]
11. Review article: the iron overload syndromes.
Siddique A; Kowdley KV
Aliment Pharmacol Ther; 2012 Apr; 35(8):876-93. PubMed ID: 22385471
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in iron chelation therapy.
Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
[TBL] [Abstract][Full Text] [Related]
13. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
14. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Kontoghiorghes GJ
Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
[TBL] [Abstract][Full Text] [Related]
15. Iron overload and allogeneic hematopoietic stem-cell transplantation.
Kanda J; Kawabata H; Chao NJ
Expert Rev Hematol; 2011 Feb; 4(1):71-80. PubMed ID: 21322780
[TBL] [Abstract][Full Text] [Related]
16. HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox.
Santos PC; Cançado RD; Pereira AC; Chiattone CS; Krieger JE; Guerra-Shinohara EM
Acta Haematol; 2010; 124(4):204-5. PubMed ID: 21071928
[No Abstract] [Full Text] [Related]
17. Iron-chelating therapy with the new oral agent ICL670 (Exjade).
Cappellini MD
Best Pract Res Clin Haematol; 2005 Jun; 18(2):289-98. PubMed ID: 15737891
[TBL] [Abstract][Full Text] [Related]
18. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.
Angelucci E; Barosi G; Camaschella C; Cappellini MD; Cazzola M; Galanello R; Marchetti M; Piga A; Tura S
Haematologica; 2008 May; 93(5):741-52. PubMed ID: 18413891
[TBL] [Abstract][Full Text] [Related]
19. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Porter JB; Shah FT
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
[TBL] [Abstract][Full Text] [Related]
20. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Kontoghiorghes GJ; Kolnagou A
Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
